CompletedNot Applicable

MELD ESAS Evolution: Assessment of the Symptomatic Burden of Patients With Advanced Chronic Liver Disease

Portugal44 participantsStarted 2024-01-01

Plain-language summary

The goal of this observational study is to understand if there is a correlation between the evolution of MELD-Na and symptomatic burden of patients with advanced chronic liver disease. All patients with chronic liver disease will be invited to participate in the study. Patients will be followed prospectively with assessment of their MELD-Na score and symptom burden, according to the Edmonton Symptom Assessment System scale.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients with chronic liver disease Exclusion Criteria: * do not sign consent to participate * patients under 18 years of age * patients who present a recurrent degree of encephalopathy, according to the West-Haven scale, equal or greater than 2

What they're measuring

MELD ESAS

Timeframe: 1 year

Trial details

NCT IDNCT06181474

SponsorUnidade Local de Saúde de Matosinhos, EPE

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Palliative Care trials